Summary
Background Tinnitus is associated with a variety of aetiologies, phenotypes, and underlying pathophysiological mechanisms, and available treatments have limited efficacy. A combination of treatments, addressing various aspects of tinnitus, might provide a viable and superior treatment strategy.
Methods In this international multicentre, parallel-arm, superiority, randomised controlled clinical trial, patients with chronic subjective tinnitus were recruited from five clinical sites across four European countries. Patients were randomly assigned using a web-based system, stratified by their hearing and distress level, to single or combination treatment of 12 weeks. Cognitive-behavioural therapy, hearing aids, structured counselling, and sound therapy were administered either alone or as a combination of two treatments resulting in ten treatment arms. The primary outcome was the difference in the change from baseline to week 12 in the total score of the Tinnitus Handicap Inventory between single and combination treatments in the intention-to-treat population. All statistical analysis were performed blinded to treatment allocation. This trial was registered at ClinicalTrials.gov (NCT04663828) and is now closed.
Findings Between Apr 16, 2021, and Sept 20, 2022, 674 patients were screened and 461 were enrolled, 230 of which were randomly assigned to single and 231 to combination treatment. Least-squares mean changes from baseline to week 12 were −11·7 for single (95% confidence interval [CI], −14·4 to −9·0) and −14·9 for combination treatments (95% CI, −17·7 to −12·1), with a significant between-group difference (p=0·034). Sound therapy alone had the lowest effect size. In contrast, cognitive-behavioural therapy and hearing aids alone had large effect sizes, which could not be further increased by combination treatment. No serious adverse events occurred.
Interpretation In this trial involving patients with chronic tinnitus, all treatment arms showed improvement in THI scores from baseline to week 12. No clear synergistic effect was observed when combining treatments, but rather a compensatory effect, where a more effective treatment offsets the clinical effects of a less effective treatment.
Funding European Union’s Horizon 2020 Research and Innovation Program (grant agreement number: 848261).
Competing Interest Statement
Details on competing interest can be found in the preprint.
Clinical Trial
NCT04663828
Clinical Protocols
https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-021-05835-z
https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-023-07303-2
Funding Statement
This clinical trial received funding from the European Unions Horizon 2020 Research and Innovation Program (grant agreement number 848261)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was independently approved by the following ethics committees: University of Regensburg, Regensburg, Germany (combined ethical approval for clinical sites Berlin and Regensburg); Katholieke Universiteit Leuven, Leuven, Belgium; Ethniko Kai Kapodistriako Panepistimo Athinon, Athens, Greece; Hospital Universitario Virgen de las Nieves/ Hospital Clinico Universitario San Cecilio, Granada, Spain.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Minor updates about the information given in the manuscript.
Data Availability
All data produced will be made available after successfull publication of the present manuscript.